ReviewCancers2021
The Growing Relevance of Immunoregulation in Pediatric Brain Tumors.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas.Molecular therapy. Oncology · 2026Article
- Opportunities in the translational pipeline for pediatric brain cancer therapies.Pediatric research · 2025Review
- The Role of Chronic Inflammation in Pediatric Cancer.Cancers · 2025Review
- OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.International journal of molecular sciences · 2024Review
- Research progress and challenges of stem cell therapy for ischemic stroke.Frontiers in cell and developmental biology · 2024Review
- Quercetin and Its Nano-Formulations for Brain Tumor Therapy-Current Developments and Future Perspectives for Paediatric Studies.Pharmaceutics · 2023Review
- Three-Dimensional Cell Culture Systems in Pediatric and Adult Brain Tumor Precision Medicine.Cancers · 2022Review
- A paediatric dysembryoplastic neuroepithelial tumour (DNET) with deregulated stem cell markers: a case report.Translational pediatrics · 2022Article
- Essential Management of Pediatric Brain Tumors.Children (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Pediatric brain tumors are genetically heterogeneous solid neoplasms. With a prevailing poor prognosis and widespread resistance to conventional multimodal therapy, these aggressive tumors are the leading cause of childhood cancer-related deaths worldwide. Advancement in molecular research revealed their unique genetic and epigenetic characteristics and paved the way for more defined prognostication and targeted therapeutic approaches. Furthermore, uncovering the intratumoral metrics on a single-cell level placed non-malignant cell populations such as innate immune cells into the context of tumor manifestation and progression. Targeting immune cells in pediatric brain tumors entails unique challenges but promising opportunities to improve outcome. Herein, we outline the current understanding of the role of the immune regulation in pediatric brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.